NSCLC remains one of the leading causes of cancer-related mortality worldwide, frequently presenting challenges due to resistance to apoptosis, the most commonly targeted cell death pathway in cancer therapies. The discovery that fosinopril induces pyroptosis, rather than apoptosis, marks a significant paradigm shift. Pyroptosis is a form of lytic programmed cell death characterized by cellular swelling, membrane rupture, and inflammatory cytokine release. This form of cell death, mediated through gasdermin family proteins, offers a promising alternative to eradicate cancer cells that evade apoptosis.

Central to this mechanism is gasdermin E (GSDME), a protein that, when cleaved, forms pores in the plasma membrane, leading to cell swelling and lysis. The study meticulously delineates how fosinopril activates caspase proteins, which in turn cleave GSDME, unleashing its pyroptotic function. This process contrasts significantly with the classical apoptosis pathway, where cells undergo controlled dismantling without eliciting inflammation, underscoring an innovative anti-cancer modality that not only kills the tumor cells but potentially activates an immune response against the tumor microenvironment.

The researchers utilized both in vitro and in vivo NSCLC models to validate fosinopril’s efficacy. At the molecular level, they observed increased expression and cleavage of GSDME following fosinopril treatment, correlating with enhanced pyroptotic markers such as cell swelling and lactate dehydrogenase (LDH) release. These pyroptotic events culminated in a marked reduction of tumor cell viability and tumor burden in animal models, suggesting a potent antitumor effect mechanistically linked to pyroptosis induction.

Further molecular analyses revealed that fosinopril’s induction of pyroptosis is intricately tied to the activation of upstream caspases, particularly caspase-3, known to bridge apoptotic and pyroptotic pathways by cleaving GSDME. This cleavage releases the GSDME N-terminal domain, which oligomerizes within the plasma membrane, generating pores that rupture the cell membrane, expelling intracellular contents and alerting the immune system. The inflammatory milieu engendered by pyroptosis could synergistically enhance anti-cancer immunity, a feature absent in apoptosis-driven therapies.

This study pioneers the repositioning of fosinopril beyond its conventional role as an angiotensin-converting enzyme (ACE) inhibitor. The molecular crosstalk between the renin-angiotensin system and pyroptotic pathways had remained largely unexplored prior to this investigation. By delineating these unexpected interactions, the authors provide a compelling rationale for clinical trials aiming to harness fosinopril’s dual functions, potentially improving NSCLC outcomes while capitalizing on its known safety profile.

The implications of this research extend deep into the clinical realm, where resistance mechanisms often limit the efficacy of targeted therapies and immunotherapies in NSCLC. Leveraging pyroptosis as a therapeutic endpoint offers a novel mode of action that might circumvent existing resistance and potentiate combination therapies. Moreover, the inflammatory aftermath of pyroptosis could enhance tumor antigen presentation and immunogenicity, possibly converting “cold” tumors resistant to immunotherapy into “hot,” more responsive ones.

Crucially, the researchers also addressed possible off-target effects and toxicity, conducting comprehensive assessments across various non-cancerous cell lines. Their data underscored a favorable therapeutic window where fosinopril selectively triggered pyroptosis in tumorigenic cells with minimal cytotoxicity in normal pulmonary tissues. This selectivity hints at mechanistic nuances within cancer cells’ microenvironment or genetic landscape that sensitize them to GSDME-mediated pyroptosis.

Mechanistically, the study delves into the signaling pathways upstream of caspase activation, uncovering involvement of mitochondrial dysfunction and reactive oxygen species (ROS) generation. Fosinopril treatment resulted in mitochondrial membrane potential disruption, elevating intracellular ROS, which serves as a pro-apoptotic and pyroptotic stimulus. These findings highlight a multifactorial process where fosinopril orchestrates a complex interplay of signals culminating in cancer cell death.

While previous studies have implicated pyroptosis in infectious and inflammatory diseases, its therapeutic exploitation in oncology remains nascent. This research serves as a landmark, suggesting that repurposing classical drugs to exploit this pathway can accelerate translational efforts. The authors propose that targeting GSDME expression or function could be customized to individual patient tumors, tailoring treatments based on the tumor’s molecular profile and pyroptotic susceptibility.

The study also explored synergistic potential by combining fosinopril with existing chemotherapeutic agents. Preliminary data indicated enhanced efficacy, possibly through additive or cooperative induction of cell death pathways. This combinatorial approach could mitigate limitations of monotherapy and offer robust therapeutic responses in diverse NSCLC patient populations.

On a broader scale, the ability to induce pyroptosis selectively in tumor cells may herald transformative shifts in cancer immunotherapy. The immunogenic nature of pyroptotic cell demise, characterized by the release of pro-inflammatory cytokines such as IL-1β and IL-18, offers a template for in situ tumor vaccination strategies. Fosinopril may thus serve as a prototype for designing drugs that couple cytotoxicity with immune activation, an intersection critical for durable cancer control.

The researchers also emphasize the need for extensive clinical validation, recognizing that translating these promising preclinical outcomes into effective human therapies will necessitate rigorous pharmacokinetic and pharmacodynamic studies. Variables such as dosage optimization, delivery modalities, and patient stratification based on GSDME expression levels will be pivotal for maximizing therapeutic benefits while minimizing adverse effects.

Moreover, the broader implications for ACE inhibitors in oncology warrant reevaluation, as fosinopril’s anticancer properties could inspire systematic screening of related compounds for pyroptotic activity. This could foster a new class of anti-cancer agents that repurpose existing drugs, thereby shortening development timelines and enhancing patient accessibility.

In conclusion, the study by Gao, Zhai, Zhang, and colleagues represents a quantum leap in lung cancer therapeutics, revealing a previously unrecognized mechanism by which fosinopril exerts antitumor effects via GSDME-dependent pyroptosis. This work not only broadens the mechanistic understanding of cancer cell death but also paves the way for innovative, immune-activating treatment strategies against NSCLC, a cancer subtype in urgent need of novel therapeutic options.

Subject of Research: The investigation focuses on fosinopril’s antitumor effects mediated through the induction of gasdermin E (GSDME)-dependent pyroptosis in non-small cell lung cancer (NSCLC).

Article Title: Fosinopril mediates antitumor efficacy by inducing GSDME-dependent pyroptosis in NSCLC.

Article References:
Gao, Y., Zhai, X., Zhang, C. et al. Fosinopril mediates antitumor efficacy by inducing GSDME-dependent pyroptosis in NSCLC. Cell Death Discov. 11, 540 (2025). https://doi.org/10.1038/s41420-025-02791-4

Image Credits: AI Generated

DOI: 21 November 2025

Ivonescimab offers a pioneering therapeutic approach by simultaneously modulating immune checkpoint pathways and angiogenesis, two fundamental mechanisms driving tumor growth and progression in NSCLC. The bispecific nature of this antibody enables it to effectively block PD-1, an immune checkpoint receptor implicated in immune evasion by cancer cells, while also inhibiting VEGF-mediated angiogenesis, a critical factor supporting tumor vascularization and metastasis. The dual blockade provides a multifaceted attack on cancer biology, augmenting the efficacy of cytotoxic chemotherapy agents such as pemetrexed and carboplatin.

The HARMONi trial enrolled 438 patients globally, with a median age of 62 years, all of whom had advanced EGFR-mutant NSCLC with disease progression despite prior exposure to third-generation EGFR tyrosine kinase inhibitors (TKIs). Notably, nearly one-quarter of participants presented with brain metastases at baseline, a subgroup traditionally associated with poor prognosis and limited therapeutic options. Patients were randomized in a double-blind, placebo-controlled design to receive either ivonescimab at 20 mg/kg combined with pemetrexed and carboplatin or chemotherapy alone, followed by maintenance therapy.

At the time of the primary analysis involving 345 patients with a median follow-up duration surpassing 22 months, the data revealed a compelling 48% reduction in the risk of disease progression or death among patients treated with ivonescimab alongside chemotherapy compared to chemotherapy monotherapy. The hazard ratio (HR) of 0.52, accompanied by a 95% confidence interval (CI) ranging from 0.41 to 0.66 and a statistically significant p-value below 0.001, underscores the robustness of the progression-free survival benefit. Median PFS extended from 4.4 months in the chemotherapy-only arm to 6.8 months in the ivonescimab group, translating into clinically meaningful delays in tumor progression.

Remarkably, the PFS advantage extended across diverse patient subpopulations, including those harboring brain metastases, where the risk of progression or death was reduced by 66% (HR 0.34; 95% CI: 0.20–0.57). This finding illuminates ivonescimab’s potential efficacy within the central nervous system (CNS), a sanctuary site often resistant to systemic therapies. Additionally, Western patients similarly benefited, suggesting consistent therapeutic effects irrespective of geographic or ethnic differences.

Final overall survival (OS) data, with a median follow-up of approximately 30 months, revealed an encouraging trend favoring the ivonescimab-containing regimen. Median OS improved from 14.0 months with chemotherapy alone to 16.8 months in the combination arm, corresponding to an HR of 0.79 (95% CI: 0.62–1.01; p=0.0570). Although this fell just short of conventional statistical significance, the trend aligns with the observed PFS benefit, supporting the therapeutic promise of this dual-targeting approach.

Further reinforcing clinical activity, the overall response rate (ORR) was considerably higher in the ivonescimab cohort at 44.7%, compared to 34.2% with chemotherapy alone. This enhanced tumor response was paralleled by improved intracranial PFS, critical given the high incidence and clinical challenges of CNS involvement in EGFR-mutated NSCLC. Together, these endpoints highlight the comprehensive anti-tumor effects mediated by ivonescimab when combined with chemotherapy.

Safety analyses from HARMONi reveal that grade 3 or higher treatment-related adverse events were observed in half of patients receiving ivonescimab plus chemotherapy, compared to 42.2% in the chemotherapy control arm. The adverse event profile was consistent with the known pharmacology of VEGF inhibition, including manageable laboratory abnormalities, reversible hypertension, and proteinuria. Importantly, treatment-related fatalities remained infrequent and were comparable between groups, at 1.8% versus 2.3%.

These favorable safety and tolerability results, alongside meaningful clinical efficacy, underscore ivonescimab as a viable and innovative therapeutic modality for patients who have exhausted standard EGFR-TKI options. Dr. Jonathan Goldman of UCLA Health, who presented these findings, emphasized that ivonescimab introduced a clinically significant and statistically robust improvement in progression-free survival while maintaining an acceptable safety profile in a notoriously difficult-to-treat patient population.

The HARMONi trial results may herald a new frontier in the treatment landscape of EGFR-mutant NSCLC, a subset of lung cancers often characterized by eventual treatment resistance and limited salvage therapies post-EGFR-TKI progression. By integrating dual pathway inhibition with chemotherapy, ivonescimab embodies a strategic fusion of immunotherapy and antiangiogenic therapy that could redefine standards of care.

The International Association for the Study of Lung Cancer (IASLC), the leading global organization dedicated exclusively to thoracic cancers, orchestrated the presentation of these compelling data. IASLC’s mission centers on accelerating lung cancer research, education, and worldwide collaboration, making the dissemination of such novel therapeutic insights pivotal to advancing clinical practice and patient outcomes.

Furthermore, the World Conference on Lung Cancer (WCLC) stands as the preeminent global platform for unveiling critical updates in lung cancer science. The 2025 meeting attracted thousands of oncology experts from over 100 countries, exemplifying the international commitment to confronting this formidable malignancy through innovation and rigorous clinical investigation.

In summary, the Phase 3 HARMONi trial substantiates the therapeutic potential of ivonescimab, a bispecific PD-1 and VEGF antibody, when paired with chemotherapy in a heavily pretreated EGFR-mutated NSCLC population. This dual-targeted strategy confers a substantial progression-free survival advantage, meaningful tumor response, and encouraging survival trends while maintaining manageable toxicity. As further research unfolds, ivonescimab may become an essential component in the sequential management of advanced lung cancer, offering renewed hope to patients with limited options following EGFR-TKI failure.

Subject of Research: Advanced EGFR-mutant non-small cell lung cancer (NSCLC) treatment following progression on 3rd-generation EGFR-TKI therapy

Article Title: Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in Patients with EGFR+ NSCLC Following 3rd-Generation EGFR-TKI Therapy

News Publication Date: September 7, 2025

Web References: www.iaslc.org

Keywords: lung cancer, non-small cell lung cancer, EGFR mutation, ivonescimab, bispecific antibody, PD-1, VEGF, chemotherapy, progression-free survival, brain metastases, immunotherapy, angiogenesis

The biological underpinnings of ICI resistance are layered and complex, involving both intrinsic tumor factors and adaptive alterations within the tumor microenvironment (TME). Tumor cells can escape immune destruction through a panoply of mechanisms, ranging from genetic and epigenetic modifications that alter antigen presentation and immune recognition to the evolution of immunosuppressive stromal components that blunt effective immune cell infiltration and effector function. Additionally, host-related influences, including dysbiosis of the gut microbiome and organ-specific pathologies, further modulate the landscape of resistance, highlighting the multifactorial nature of immune escape in NSCLC.

Crucially, while the molecular and cellular routes to resistance are diverse, they often converge on a shared endpoint: the establishment of an immunosuppressive TME. This hostile milieu orchestrates a blockade of antitumor immunity, rendering ICIs ineffective despite their initial promise. Thus, current research and therapeutic strategies have increasingly focused on disrupting or reprogramming the immunosuppressive circuitry within the TME to restore effective immune surveillance and cytotoxicity.

Emerging antibody-based modalities constitute a major pillar of these efforts. Innovative constructs such as bispecific antibodies, T cell engagers, and antibody-drug conjugates are designed to simultaneously target multiple immunoregulatory pathways or deliver cytotoxic payloads selectively to malignant cells. These multifunctional biologics aim to circumvent resistance mechanisms by either reinvigorating exhausted T cells or directly eliminating suppressive cell populations within the tumor niche.

Beyond antibodies, small molecule targeted therapies offer additional avenues to counteract resistance. By inhibiting tumor-intrinsic signaling pathways that promote immune evasion or by reshaping the TME through modulation of stromal or myeloid cell functions, these agents may re-sensitize tumors to immune checkpoint blockade. Moreover, combination regimens that integrate targeted inhibitors with ICIs are under active clinical investigation, seeking synergistic effects against refractory NSCLC.

Adoptive cell therapies also hold promise as next-generation immune interventions. Techniques such as chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte (TIL) expansion are being refined to enhance specificity, persistence, and tumor homing in solid tumors like NSCLC. These personalized immunotherapies may overcome some intrinsic barriers posed by the tumor and its microenvironment, offering potential salvage options for patients with checkpoint-resistant disease.

Therapeutic cancer vaccines and intratumoral immunotherapies represent additional innovative frontiers. These strategies aim to boost tumor antigen presentation and prime endogenous immune responses directly within the tumor milieu. By localizing immune activation and circumventing systemic immune suppression, they may create focal points of antitumor immunity conducive to durable disease control.

Despite the proliferation of novel therapeutic approaches, the identification and validation of robust predictive biomarkers for immune resistance remain a critical unmet need. Current biomarkers, often derived from sequencing or immunohistochemical analyses, provide incomplete prognostication, reflecting the heterogeneity and dynamic nature of resistance mechanisms. The complexity is compounded by the spatial and temporal variability in tumor and immune cell phenotypes, necessitating longitudinal and multifaceted biomarker strategies.

To effectively navigate this complexity, adaptive, hypothesis-generating clinical trial designs have garnered attention. Such flexible frameworks enable real-time integration of biomarker data and allow brisk incorporation of emerging therapeutic concepts. This iterative approach may accelerate the discovery of effective combination regimens and personalized treatment strategies tailored to the evolving resistance profiles of individual patients.

In parallel, advances in spatial transcriptomics, multiplex immunofluorescence, and single-cell sequencing technologies are shedding light on the intricate cellular interplay within the NSCLC microenvironment. These tools facilitate high-resolution mapping of immune and stromal components, revealing potential vulnerabilities and resistance drivers that may be therapeutically exploitable. Integrating these molecular insights into clinical practice remains a critical translational challenge.

Furthermore, the role of the gut microbiome in shaping systemic immunity and modulating responses to ICIs has emerged as a fascinating area of study. Dysbiosis—disruption of the normally balanced microbial communities—can negatively impact immune competence and foster resistance. Therapeutic manipulation of the microbiome through probiotics, antibiotics, or fecal microbiota transplantation is under exploration as an adjunct to immunotherapy.

Organ-specific microenvironments, such as those in the brain or liver where metastatic lesions commonly reside, also impose unique immunological constraints. Understanding how these sites influence immune cell trafficking and function will be pivotal in designing therapies that overcome tissue-specific barriers to checkpoint inhibitor efficacy.

Taken together, these insights underscore a paradigm shift in NSCLC treatment from monolithic checkpoint blockade to sophisticated, multi-modal strategies tailored to dismantle the immunosuppressive fortress encasing resistant tumors. Interdisciplinary collaboration among oncologists, immunologists, molecular biologists, and bioinformaticians is crucial in accelerating this progress.

While substantial challenges persist, the trajectory of research efforts offers a cautiously optimistic outlook. Early-phase clinical trials of combination regimens and novel immune-activating platforms have reported encouraging signals of efficacy. Continued refinement of therapeutic approaches and biomarker-guided patient selection promise to enhance response rates and extend survival benefits beyond what was once achievable.

As the field moves forward, a comprehensive understanding of the dynamic interplay between tumor biology, the immune milieu, and host factors will be essential. This holistic perspective will enable the design of rational interventions to preempt, delay, or reverse resistance to ICIs in NSCLC, transforming a currently intractable problem into a manageable clinical reality.

In summary, the battle against immune checkpoint inhibitor resistance in NSCLC is entering a new chapter defined by scientific ingenuity and clinical innovation. By harnessing emerging technologies, embracing adaptive trial designs, and integrating multidimensional biomarkers, researchers are steadily unraveling the complexities that have long thwarted durable immunotherapeutic success. The coming years may well witness the translation of these advances into tangible improvements in patient care worldwide.

Subject of Research: Resistance to immune-checkpoint inhibitors in advanced non-small-cell lung cancer and emerging therapeutic strategies.

Article Title: Treatment of NSCLC after chemoimmunotherapy — are we making headway?

Article References: Reck, M., Frost, N., Peters, S. et al. Treatment of NSCLC after chemoimmunotherapy — are we making headway?. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01061-7

Image Credits: AI Generated

DOI: 10.1038/s41571-025-01061-7

Keywords: non-small-cell lung cancer, immune-checkpoint inhibitors, immune resistance, tumor microenvironment, bispecific antibodies, T cell engagers, adoptive cell therapy, therapeutic vaccines, biomarker-driven studies

Non-small cell lung cancer accounts for approximately 85% of lung cancer cases and remains a leading cause of cancer-related mortality worldwide. Despite advances in targeted treatments, resistance to therapies such as KRAS inhibitors persists, often leading to disease progression. KRAS mutations, particularly KRAS G12C, have long been an elusive target until the development of covalent inhibitors like adagrasib, which specifically target this mutant protein. However, monotherapy with adagrasib, while effective initially, frequently leads to acquired resistance, underscoring the urgent need for innovative combinatorial approaches.

The current study, led by Lu, H. and colleagues, centers on panobinostat, a potent histone deacetylase (HDAC) inhibitor known to modulate gene expression and impact tumor cell proliferation and survival. Previous research has hinted at HDAC inhibitors’ potential to sensitize cancer cells to other treatments by altering epigenetic landscapes. Here, the scientists propose that panobinostat can enhance adagrasib-induced cytotoxicity by promoting autophagic pathways, thereby effectively doubling down on tumor cell demise.

Autophagy, a tightly regulated catabolic process responsible for degrading and recycling cellular components, is a double-edged sword in cancer biology. While in some contexts autophagy supports tumor survival under stress conditions, its excessive activation can precipitate autophagic cell death—a non-apoptotic mechanism distinct from classical programmed cell death. The authors demonstrate that panobinostat triggers this autophagic flux in NSCLC cells, which, when combined with adagrasib treatment, results in synergistic suppression of tumor viability.

Through a series of rigorous in vitro experiments, multiple NSCLC cell lines harboring the KRAS G12C mutation were exposed to adagrasib alone or in combination with panobinostat. Cellular viability assays revealed a significant increase in apoptosis and autophagic markers in the combination therapy group compared to single treatment arms. By employing autophagy inhibitors alongside the drug regimen, the researchers confirmed that autophagy was a pivotal contributor to the enhanced cell death observed, rather than a bystander effect.

Delving deeper into the mechanistic underpinnings, the study elucidates that panobinostat’s epigenetic modulation leads to upregulation of key autophagy-related genes, such as LC3 and Beclin-1, thereby priming the cells for enhanced autophagic response upon exposure to adagrasib. This coordinated upregulation underscores the potential of epigenetic therapy as a partner to conventional targeted drugs, opening new avenues for combinatorial regimens in lung cancer management.

Beyond cell cultures, the team assessed this drug synergy in xenograft mouse models, observing marked tumor regression and prolonged survival in animals treated with both panobinostat and adagrasib compared to controls. Importantly, toxicity assessments revealed that the combination was tolerated well, with minimal adverse effects, strengthening the case for clinical evaluation of this therapeutic strategy.

This dual-triggering of apoptosis and autophagy presents an elegant strategy to tackle the pervasive issue of resistance in KRAS mutant NSCLC. By manipulating intrinsic cell death pathways, the dual treatment dismantles the cellular defenses that often thwart single-agent therapies. The findings also spark a broader implication that HDAC inhibitors could be harnessed to bolster the efficacy of a wide range of targeted cancer therapies beyond NSCLC.

The research further underscores the complexity of autophagy’s role in cancer, advocating for context-specific modulation rather than blunt inhibition. In this setting, triggering autophagy facilitated drug-induced cytotoxicity rather than promoting tumor survival, highlighting the necessity of precision medicine approaches tailored to the molecular landscape of each cancer subtype.

Intriguingly, the authors note that this synergistic effect may also intersect with immune-modulatory functions, as HDAC inhibitors are known to influence tumor microenvironment and immune checkpoints. While beyond the scope of this initial investigation, this raises compelling prospects for integrating immune-based therapies with panobinostat and adagrasib combinations in future clinical trials.

The study’s advanced use of molecular probes and biochemical assays helped paint a detailed picture of intracellular events, reinforcing the significance of comprehensive mechanistic studies in translational oncology. The revelation that panobinostat primes tumor cells to succumb more readily to adagrasib aligns with the growing ethos that combinational strategies are imperative for overcoming cancer’s adaptive prowess.

Given the mounting evidence, clinical oncologists are likely to watch closely as panobinostat is ushered into trials combined with adagrasib in KRAS mutant NSCLC patients. If these promising preclinical results translate to the clinic, it could radically redefine therapeutic paradigms for one of the most challenging lung cancer subsets.

This study also serves to remind the scientific community about the value of repurposing existing drugs like panobinostat, initially approved for hematological malignancies, in solid tumors where unmet clinical needs abound. By leveraging known pharmacological agents with newly elucidated mechanisms, research can accelerate the bench-to-bedside timeline, offering tangible benefits to patients sooner.

The ethical and economic impact of such combinatorial treatments must also be considered, as lung cancer’s global burden disproportionately affects populations with limited access to expensive therapies. Targeting autophagy via HDAC inhibition may offer a more cost-effective means to sensitize tumors, potentially improving outcomes in diverse healthcare settings.

Future research directions proposed by the authors include deciphering biomarkers predictive of response to this drug combination, as well as expanding investigations into other KRAS mutations and cancer types where autophagy modulation could be exploited therapeutically. This comprehensive framework will be critical for tailoring treatments to individual molecular profiles.

In sum, this seminal work by Lu et al. propels our understanding of NSCLC biology forward by bridging epigenetic therapy with targeted inhibition through autophagy induction. The elegant synergy between panobinostat and adagrasib heralds a new chapter in the relentless battle against lung cancer, promising hope for improved survival and quality of life for patients worldwide.

As scientists continue to unravel the intricacies of cancer’s survival tactics, the integration of multi-modal therapeutic strategies that blend targeted drugs with epigenetic and metabolic modulators is poised to deliver unprecedented clinical advances. This study stands as a beacon, exemplifying how meticulous molecular dissection can translate into transformative treatment concepts.

The potential of this breakthrough extends beyond lung cancer, offering a scalable blueprint for combatting other malignancies where resistance mechanisms undermine targeted therapy success. The road ahead will undoubtedly involve complex clinical validation, yet the horizon gleams with optimism fueled by these innovative insights into autophagy and epigenetic synergy.

Subject of Research: Human Non-Small Cell Lung Cancer (NSCLC) and the synergistic effects of panobinostat and adagrasib on triggering autophagy-induced cell death.

Article Title: Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer.

Article References:
Lu, H., Fu, W., Xia, Y. et al. Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer. Cell Death Discov. 11, 360 (2025). https://doi.org/10.1038/s41420-025-02657-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02657-9

The study, known as ALEK-B, assessed this combination as a first-line treatment option, challenging current standards that typically rely upon monotherapy with targeted ALK inhibitors. For years, alectinib has been a front-runner among ALK inhibitors, exhibiting potent activity against ALK-rearranged NSCLC and yielding improved progression-free survival compared to earlier generations of targeted drugs. However, the emergence of resistance mechanisms and intratumoral heterogeneity have limited its long-term effectiveness. By synergizing with bevacizumab, which disrupts tumor vasculature and starves cancer cells of essential nutrients, the therapy aims to augment anti-tumor responses and delay resistance development.

The trial was designed as a single-arm, phase 2 study encompassing a cohort of patients diagnosed with ALK-positive NSCLC who had not received prior systemic therapy. This design allowed investigators to meticulously evaluate the safety profile, objective response rates, and durability of clinical responses directly attributable to the combination treatment, bypassing confounding variables present in randomized controlled trials. Researchers employed rigorous inclusion criteria, ensuring patient homogeneity based on molecular diagnostics confirming ALK rearrangements through fluorescence in situ hybridization and next-generation sequencing techniques.

From a mechanistic standpoint, alectinib inhibits the aberrant tyrosine kinase activity resulting from ALK fusion proteins, which drive proliferation and survival in affected cancer cells. Bevacizumab, conversely, targets vascular endothelial growth factor A (VEGF-A), a pivotal mediator of angiogenesis. By neutralizing VEGF-A, bevacizumab reduces neovascularization, consequently impairing tumor oxygenation and nutrient supply. The rationale for this dual approach rests on the hypothesis that suppressing both the molecular oncogenic driver and its supportive microenvironment will yield synergistic antitumor effects stronger than monotherapies alone.

Results from the ALEK-B trial demonstrated encouraging outcomes. Patients receiving the combination experienced significant tumor shrinkage, with objective response rates exceeding historical controls treated with alectinib alone. Furthermore, progression-free survival data suggested prolonged disease control, while preliminary overall survival metrics painted an optimistic picture of extending patient lifespan beyond what current therapies offer. Importantly, the safety profile reported in the trial indicated manageable adverse events consistent with known toxicities of the individual agents, reinforcing the feasibility of combining these two targeted therapies in clinical practice.

One of the notable breakthroughs of this regimen is its potential to circumvent or delay the emergence of resistance mutations on the ALK gene, a formidable challenge in targeted lung cancer therapies. Resistance to ALK inhibitors often emerges through secondary mutations or alternative signaling pathway activation. By concurrently impairing angiogenesis, bevacizumab introduces a novel therapeutic pressure that may reduce tumor adaptability, curtail clonal evolution, and foster more durable responses.

The implications of the ALEK-B trial extend beyond immediate clinical benefits. This work represents a paradigm shift emphasizing combination regimens that integrate targeted kinase inhibition with tumor microenvironment modulation, encouraging future exploration of similar strategies across diverse oncogenic drivers and solid tumors. Additionally, this trial underscores the significance of biomarker-driven enrollment, ensuring that patients most likely to benefit from such tailored interventions are identified and treated accordingly.

While the ALEK-B study provides compelling evidence for the clinical utility of alectinib plus bevacizumab, further randomized studies are warranted to firmly establish this regimen as a new standard of care. Ongoing trials with larger sample sizes and longer follow-ups will clarify the durability of responses, optimal dosing schedules, and potential synergistic toxicities. Equally important will be investigating resistance mechanisms that may arise during combined therapy, which could inform iterative improvements in treatment design.

On a molecular level, the study sparks intense curiosity about how angiogenesis inhibition influences the tumor microenvironment in ALK-rearranged NSCLC. Beyond just pruning blood vessels, VEGF blockade has been implicated in modulating immune cell infiltration, stromal interactions, and hypoxia-driven signaling cascades. Understanding these intricate networks may open avenues for incorporating immunotherapeutic agents alongside ALK inhibitors and VEGF-targeted treatments, crafting a multipronged assault against lung cancer.

The study’s methodology also leveraged cutting-edge imaging modalities and biomarker analyses to monitor tumor response dynamically. Advanced radiographic techniques allowed precise quantification of vascular changes and tumor burden, while circulating tumor DNA (ctDNA) assays provided real-time insights into molecular evolution, enabling personalized adjustments in therapeutic strategies. These sophisticated tools exemplify how translational research is tightly interwoven with clinical trials to accelerate discoveries from bench to bedside.

Beyond the immediate patient population, findings from ALEK-B may stimulate drug development aimed at novel combinations pairing tyrosine kinase inhibitors with anti-angiogenic drugs in other genetic contexts. Oncologists envision a future where such regimens become customizable based on comprehensive genomic and transcriptomic profiling, maximizing efficacy while minimizing toxicity.

In conclusion, the ALEK-B trial represents a bold step forward in the treatment of ALK-rearranged NSCLC. By strategically combining alectinib’s potent ALK inhibition with bevacizumab’s anti-angiogenic capabilities, researchers have laid the groundwork for a potentially transformative approach in managing this challenging disease. If validated in larger studies, this dual-targeted therapy could redefine first-line treatment paradigms, offering patients more durable responses and improved survival outcomes. The success of ALEK-B underscores the power of rational drug combinations designed not only to target oncogenic drivers but also to reshape the tumor microenvironment, heralding a new era of precision oncology.

—

Subject of Research: Combination therapy with alectinib and bevacizumab as a first-line treatment for ALK-rearranged non-small cell lung cancer

Article Title: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Article References:

Arrieta, O., Lara-Mejía, L., Rios-Garcia, E. et al. Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial. Nat Commun 16, 4553 (2025). https://doi.org/10.1038/s41467-025-59744-9

Image Credits: AI Generated